MedTrace Logo

Assessment of the Effect of Food on ABT-143 Bioavailability

NCT00719693 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2012-09-28

No results posted yet for this study

Summary

Single-dose, open-label, two-period crossover study of ABT-143

Conditions

  • Pharmacokinetic Variables

Interventions

DRUG

ABT-143 ( rosuvastatin calcium and fenofibric acid )

one dose under low-fat meal condition

DRUG

ABT-143 (rosuvastatin calcium and fenofibric acid )

one dose under fasting meal condition

Sponsors & Collaborators

Principal Investigators

  • Torbjörn Lundström, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00719693 on ClinicalTrials.gov